Compound and salt thereof, use thereof in preparing cancer treatment drugs and kinase inhibitors, and cancer treatment drugs

The deuterated CHMFL-FLT3-122 compound addresses the issues of drug resistance and side effects in FLT3-itd-positive AML patients, achieving highly efficient inhibition of FLT3-itd-positive AML cells and safe drug administration, thus improving treatment efficacy and safety.

CN117903141BActive Publication Date: 2024-11-05JIANG SU PHARMAMAXCORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311747732.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-19
Publication Date
2024-11-05
Estimated Expiration
2043-12-19

AI Technical Summary

Technical Problem

Existing FLT3 kinase inhibitors have resistance issues when treating FLT3-itd-positive AML patients, and first- and second-generation drugs have significant side effects, failing to meet clinical needs.

Method used

Develop deuterated CHMFL-FLT3-122 compounds and their pharmaceutically acceptable salts for the preparation of highly potent FLT3 kinase inhibitors. Improve inhibitory activity against FLT3-itd-positive AML cells through structural modification and optimize pharmacokinetic properties.

Benefits of technology

Compounds 2 and 3 exhibited significant inhibitory effects on FLT3-itd-positive AML cells, reducing the dosage and toxic side effects, and demonstrated potent tumor suppression in in vitro and in vivo experiments, improving pharmacokinetic properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117903141B_ABST
    Figure CN117903141B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of drug synthesis, and specifically relates to a compound and a salt thereof, use thereof in preparing a drug for treating cancer and a kinase inhibitor, and a drug for treating cancer. The present invention provides a CHMFL-FLT3-122 compound deuterated at a specific position and a pharmaceutically acceptable salt thereof, provides the use of the above compound or its pharmaceutically acceptable salt in preparing a drug for treating cancer and a kinase inhibitor, and also provides a drug for treating cancer. The compound and its pharmaceutically acceptable salt provided by the present invention have strong anticancer activity, good metabolic stability and pharmacokinetic properties, and excellent application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of drug synthesis, and relates to a compound and a salt thereof, uses of the compound in preparing a drug for treating cancer and a kinase inhibitor, and a drug for treating cancer. Background Art

[0002] Blood cells in the blood or tissues all originate from hematopoietic stem cells. Hematopoietic stem cells differentiate step by step to produce a variety of mature blood cells, a process called hematopoiesis. Only when the number of mature blood cells and platelets is maintained at a certain level can the body's physiological functions function normally. When blood cell differentiation is blocked and proliferation is out of control, the amount of mature blood cells cannot be replenished, and immature blood cells are produced in large quantities, occupying the living space of normal blood cells, competing for nutrients, and causing body dysfunction, which is the occurrence of leukemia. Leukemia patients are prone to continuous bleeding and decreased immunity, which seriously endangers the patient's life.

[0003] Leukemia can be divided into four main types, namely acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL). AML is the most common type of leukemia and also the type with the highest mortality rate. With the continuous development of gene sequencing technology, researchers have found that more and more gene mutations play an important role in the onset of AML. Among them, FLT3 kinase mutation is the most common mutation in AML, and patients with FLT3 gene mutations often have a poor prognosis.

[0004] The FLT3 kinase structure includes an extracellular region, a transmembrane region, a juxtamembrane region, two kinase regions separated by an intermediate insertion structure, and finally a C-terminal terminal structure. Under normal physiological conditions, when there is no FLT3 ligand (FL), the juxtamembrane structure of FLT3 will inhibit the formation of FLT3 dimerization. When FL is present, it binds to the extracellular receptor region to cause FLT3 dimerization, causing structural changes in the kinase region, phosphorylating downstream signaling proteins such as PI3K, Ras, and STAT5, thereby activating downstream signaling pathways, and regulating cell growth and proliferation through a series of signal transduction. In 1996, when researchers tested AML patients, they found that up to 30% of patient samples had FLT3-ITD (tandem duplication mutation of the juxtamembrane region of FLT3 kinase) mutations. Subsequently, in a study in 2001, it was found that 5% of patients had FLT3-TKD point mutations (tyrosine kinase region point mutations). Both mutations can activate FLT3 kinase independently of FL binding. When FLT3-ITD mutation is present, it causes FL-independent activation and activates the downstream signaling pathways of PI3K, Ras, and STAT5, promoting cell proliferation and leading to the occurrence of AML.

[0005] The first generation of FLT-3 inhibitors that have been launched on the market are all multi-target inhibitors, and the representative varieties are sorafenib (2005), sunitinib (2006), ponatinib (2013), and cabozantinib (2013). Since the first generation of drugs are all multi-target drugs, there are some inevitable side effects, such as diarrhea, anorexia, fatigue, nausea, rash, acne, joint pain, etc. As a result, more efficient FLT-3 inhibitors have been developed and approved for marketing, and their indications are mainly concentrated in acute myeloid leukemia. Midostaurin has obtained FDA breakthrough status and became the first kinase inhibitor targeting FLT3. As a second-generation FLT3 inhibitor, quizartinib has good selectivity and inhibitory activity for FLT3. The FLT3 kinase inhibitors currently developed have achieved good therapeutic effects in clinical trials, but with the continuous advancement of FLT3 inhibitors in clinical testing, the problem of drug resistance has quickly emerged, and there is still an unmet medical need for FLT3-ITD-positive AML.

[0006] Based on the structure of a recently reported BTK kinase inhibitor, ibrutinib, China has carried out structural modification to obtain the compound CHMFL-FLT3-122 (abbreviated as D18), which has high inhibitory activity against FLT3-ITD-positive AML cell lines. In the cellular environment, it affects the FLT3-itd-mediated signaling pathway and is selective between BTK kinase and FLT3 kinase. It has now entered Phase II clinical trials and is a potential candidate drug for the treatment of FLT3-itd-positive AML.

[0007] In summary, for FLT3-itd-positive AML patients, providing compounds with better performance and richer selection and high inhibitory activity is of great practical significance. Summary of the invention

[0008] The present invention provides a deuterated CHMFL-FLT3-122 compound and a pharmaceutically acceptable salt thereof, provides the use of the above compound or its pharmaceutically acceptable salt in the preparation of a drug for treating cancer and a kinase inhibitor, and also provides a drug for treating cancer, with the aim of enhancing the efficacy of the drug and / or improving the safety of the drug.

[0009] The present invention provides a compound or a pharmaceutically acceptable salt thereof, the structure of which is as follows:

[0010]

[0011] The present invention also provides another compound or a pharmaceutically acceptable salt thereof, the structure of which is as follows:

[0012]

[0013] Furthermore, the pharmaceutically acceptable salt is a salt formed between the compound of the present invention and an acid.

[0014] Further, the pharmaceutically acceptable salt is selected from one or more of phosphate, camphorsulfonate, hydrochloride, hydrobromide, hydrofluoride, sulfate, nitrate, format, acetate, propionate, oxalate, malonate, succinate, fumarate, maleate, lactate, malate, tartrate, citrate, picrate, methanesulfonate, trifluoromethanesulfonate, toluenesulfonate, and benzenesulfonate.

[0015] Preferably, the pharmaceutically acceptable salt is hydrochloride.

[0016] The present invention also provides a use of the above compound or a pharmaceutically acceptable salt thereof in preparing a drug for treating cancer.

[0017] Furthermore, the use is the use of the above-mentioned compound or its pharmaceutically acceptable salt as a novel FLT3kinase tyrosine kinase inhibitor to reduce or inhibit the mutant FLT3 kinase activity of cells or subjects and to prevent or treat cell proliferative disorders and / or FLT3-related disorders in subjects.

[0018] Furthermore, the cancer is selected from lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, liver cancer, glioblastoma, solid tumors, non-small cell lung cancer, papillary renal cell carcinoma, and melanoma.

[0019] The present invention also provides a use of the above compound or a pharmaceutically acceptable salt thereof for preparing a FLT3 kinase inhibitor.

[0020] The present invention also provides a drug for treating cancer, which is a preparation prepared by using the above compound or its pharmaceutically acceptable salt as an active ingredient and adding pharmaceutically acceptable auxiliary materials.

[0021] Beneficial Effects

[0022] The compound and pharmaceutically acceptable salt thereof provided by the present invention have strong anti-cancer activity.

[0023] The compounds and pharmaceutically acceptable salts thereof provided by the present invention also have good metabolic stability and pharmacokinetic properties. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Shown is the cell cycle distribution of MOLM-13 cells under the action of compounds D18 and D18-D6.

[0025] Figure 2 Shown is the cell cycle distribution of MV4-11 cells under the action of compounds D18 and D18-D6.

[0026] Figure 3 Shown are MOLM-13 and MV4-11 cell colonies under the action of compounds D18 and D18-D6.

[0027] Figure 4 A shows the changes in the body weight of mice after administration. Figure 4 B shows the changes in tumor size in mice after drug administration. Figure 4 C shows the actual photo of the final tumor in the mouse after drug administration. Figure 4 D shows the final tumor weight in mice after drug administration. DETAILED DESCRIPTION

[0028] The spatial shape and volume of deuterium are basically the same as those of hydrogen. When hydrogen in the molecular structure of a drug is replaced by deuterium, the biological activity and selectivity of the original drug are usually retained in the deuterated drug. The deuterated drug formed has an isotope effect and regulates the relevant processes of drug metabolism. However, since the metabolic process of the biological system is very complex, the pharmacokinetic properties of drugs in vivo also show corresponding complexity due to the influence of many factors. Therefore, compared with non-deuterated drugs, the changes in the pharmacokinetic properties of deuterated drugs show great contingency and unpredictability. For example, deuterium at certain sites not only cannot prolong the half-life, but may shorten it (Scott L. Harbeson, Roger D. Tung. Deuterium in Drug Discovery and Development, P405-406).

[0029] The present invention prepares a series of deuterated products based on CHMFL-FLT3-122 (abbreviated as D18) compound, and unexpectedly discovers two new compounds which have significant inhibitory effects on human acute monocytic leukemia cell line MV4-11 and human acute myeloid leukemia cell line MOLM-13.

[0030] The structure of compound D18:

[0031]

[0032] The series of compounds tested in the present invention include compounds 2 to 15, and the structures are as follows.

[0033] The structure of compound 2:

[0034]

[0035] The structure of compound 3:

[0036]

[0037] The structure of compound 4:

[0038]

[0039] The structure of compound 5:

[0040]

[0041] The structure of compound 6:

[0042]

[0043] The structure of compound 7:

[0044]

[0045] The structure of compound 8:

[0046]

[0047] The structure of compound 9:

[0048]

[0049] The structure of compound 10:

[0050]

[0051] The structure of compound 11:

[0052]

[0053] The structure of compound 12:

[0054]

[0055] The structure of compound 13:

[0056]

[0057] The structure of compound 14:

[0058]

[0059] The structure of compound 15:

[0060]

[0061] The study found that among the above compounds, compound 2 and compound 3 have unique and significant inhibitory effects on human acute monocytic leukemia cell line MV4-11 and human acute myeloid leukemia cell line MOLM-13. In addition, compared with D18, compound 2 and compound 3 show better pharmacokinetic properties, which can greatly reduce the dosage and toxic side effects.

[0062] Experimental instruments and reagents used in the present invention

[0063] Experimental instruments: Bruker AVIII 400MHz nuclear magnetic resonance instrument; Bruker AV NEO 600MHz nuclear magnetic resonance instrument; NICOLET Nexus 470FT-IR infrared spectrometer; Waters ACQUITY Arc high performance liquid chromatograph; QDA (ESI) mass spectrometer detector; Agilent G7890-5975C (EI) gas chromatograph-mass spectrometer; Thermo Scientific LTQOrbitrap XL high resolution mass spectrometer.

[0064] Reagent: Compound C 27 H 30 N6O3, ethyl acetate, dioxane, sodium bicarbonate, hydrogen chloride, 2-dimethylaminoacetic acid, HATU, DIPEA, EtOAc, dichloromethane, chloroacetyl chloride, MeOH, deuterated dimethylamine d6 hydrochloride, triethylamine, potassium iodide, anhydrous sodium sulfate, petroleum ether, anhydrous ethanol, acetonitrile, etc. All reagents were commercially available analytically pure products and used directly after purchase.

[0065] Synthesis of compound D18

[0066] According to the following reaction formula, the raw material (1 g, 2.06 mmol) was weighed and dissolved in ethyl acetate (20 mL), and 4N hydrogen chloride dioxane solution was added under an ice-water bath, followed by reaction at room temperature for 2 hours. The reaction was complete when detected by TLC, and the solvent was evaporated under reduced pressure to obtain a white solid. Ethyl acetate and water were added, and 2N sodium bicarbonate solution was added, and the mixture was extracted with ethyl acetate. The ethyl acetate layers were combined and washed with saturated brine, dried, and the solvent was evaporated under reduced pressure to obtain 865 mg of a white solid.

[0067]

[0068] According to the following reaction formula, 2-dimethylaminoacetic acid (22 mg, 0.21 mmol), HATU (80 mg, 0.21 mmol) and DIPEA (35 μL, 0.20 mmol) were added to a solution of raw material (80 mg, 0.21 mmol) in DMF (4 mL). The reaction mixture was stirred for 5 h. It was then diluted with EtOAc (50 mL), washed with water (20 mL × 3) and saturated brine (30 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (0-10% MeOH in dichloromethane) to give white solid compound D-18 (67 mg, 68%). 1 H NMR (400 MHz, DMSO-d6):δ H 8.26(d,J=8.2Hz,1H),7.71–7.61(m,2H),7.43(t,J=7.8Hz,2H),7.24–7.08(m ,5H),4.83(m,0.5H),4.66(s,0.5H),4.46(dd,J=12.6,4.3Hz,1H),4.24–4.08( m,1H),3.93(d,J=13.4Hz,1H),3.65(s,0.5H),3.56–3.05(m,3H),2.92(s,0.5 H), 2.36 (s, 4H), 2.27 (s, 4H), 2.12 (d, J = 4.3Hz, 1H), 1.90 (m, 1H), 1.69 (s, 1H). 13C NMR (100 MHz, DMSO-d6)δ C 166.7,158.2,157.1,156.3,155.7,153.9,143.3,130.1,127.9,123.8,120.1,119.0,97.4,60.7,52.6,52.0,49.0,45.4,44.9,44.8,41.4,29.4,24.5.

[0069]

[0070] Synthesis of Compound 2 (D18-D6)

[0071] According to the following reaction formula, DIPEA (36.5 μL, 0.21 mmol) and chloroacetyl chloride (17 μL, 0.21 mmol) were added to a solution of raw material (80 mg, 0.21 mmol) in dichloromethane (10 mL) at 0 ° C. The resulting mixture was stirred for 3 minutes. It was then quenched with MeOH (5 mL), concentrated, and purified by silica gel column chromatography (dichloromethane: methanol 100: 1 to 30: 1) to obtain an amide compound (89 mg) as a white solid.

[0072] The above white solid was dissolved in dry acetonitrile (5 mL), deuterated dimethylamine d6 hydrochloride (88 mg, 1 mmol), triethylamine (140 μL, 2 mmol) and potassium iodide (17 mg, 0.1 mml) were added, and the reaction was heated to 40°C for 12 hours. Water was added to quench the reaction, and the mixture was extracted three times with ethyl acetate. After drying, the mixture was purified by silica gel column chromatography (dichloromethane: methanol 50:1 to 10:1). The product D-18-d6 was 75 mg of a white solid with a total yield of 75%. 1 H NMR (400 MHz, DMSO-d6):δ H 8.28(d,J=8.3Hz,1H),7.68(d,J=8.2Hz,2H),7.49–7.39(m,2H),7.16(m,5H),4.83(m,0.5H),4.66(m,0.5H),4.49(dd,J=12.5,4.2Hz,1 H),4.19(m,1H),4.10–3.95(m,1H),3.63(dd,J=13.2,9.7Hz,1H),3.35–2.81(m,4H),2.36–2.05(m,2H),1.91(m,1H),1.77–1.42(m,1H). 13 C NMR (100 MHz, DMSO-d6):δ C167.6,158.2,157.1,156.3,155.6,153.9,143.3,130.1,127.9,123.8,118.9,97.5,61.4,53.1,52.1,49.3,45.4,45.4,45.1,41.7,29.5,24.7.

[0073]

[0074] Synthesis of compound 3 (D18-D3)

[0075] According to the following reaction formula, DIPEA (36.5 μL, 0.21 mmol) and chloroacetyl chloride (17 μL, 0.21 mmol) were added to a solution of raw material (80 mg, 0.21 mmol) in dichloromethane (10 mL) at 0 ° C. The resulting mixture was stirred for 3 minutes. It was then quenched with MeOH (5 mL), concentrated, and purified by silica gel column chromatography (dichloromethane: methanol 100: 1 to 30: 1) to obtain an amide compound (89 mg) as a white solid. The above solid was dissolved in dry acetonitrile (5 mL), deuterated dimethylamine d3 hydrochloride (88 mg, 1 mmol), triethylamine (140 μL, 2 mmol) and potassium iodide (17 mg, 0.1 mml) were added, and the reaction was heated to 40°C for 12 hours. Water was added to quench the reaction, and the mixture was extracted three times with ethyl acetate. After drying, the mixture was purified by silica gel column chromatography (dichloromethane: methanol 50:1 to 10:1). The product D-18-d3 was 71 mg of a white solid with a total yield of 70%.

[0076]

[0077] Effects of D18 and deuterated drugs on cancer cell proliferation

[0078] The inhibitory effect on cancer cell proliferation was evaluated by measuring the effects of D18 and deuterated series drugs on cancer cell proliferation. Human acute monocytic leukemia cell line MV4-11 (expressing FLT3 / ITD mutant gene) and human acute myeloid leukemia cell line MOLM-13 (expressing FLT3 / ITD mutant gene and wild-type FLT3 gene) were selected. Different concentrations of the above compounds (25nM, 50nM, 100nM, 200nM, 400nM in DMSO) were added to the above cells and incubated for 72 hours. Cell Counting Kit-8 (abbreviated as CCK-8) reagent was used to detect the absorbance at 450nm in an ELISA instrument to obtain the OD value, and the IC50 was further calculated. The experimental results are shown as follows.

[0079] Table 1 IC of compounds against MOLM-13 and MV4-11 cells 50 value

[0080]

[0081] The results showed that among the deuterated compounds, compounds 2 and 3 showed unique inhibitory effects on cancer cell proliferation. IC values ​​of compounds 2 and 3 on MOLM-13 and MV4-11 cells 50 The values ​​are significantly lower than those of other deuterated compounds and also lower than those of compound D18 to a greater extent, indicating that its inhibitory effect on MOLM-13 and MV4-11 cells is not only significantly better than that of other deuterated compounds, but also better than that of compound D18 to a greater extent. (IC 50 , half maximal inhibitory concentration, also known as 50% inhibitory concentration, refers to the concentration of drug that induces 50% apoptosis of tumor cells, that is, the drug concentration corresponding to the ratio of apoptotic cells to the total number of cells equals 50%. IC 50 The value can be used to measure the ability of a drug to induce apoptosis of tumor cells. The lower the value, the stronger the induction ability.

[0082] Effects of D18 and D18-D6 on cell cycle

[0083] The effects of D18 and D18-D6 on the cell cycle distribution of human acute monocytic leukemia cell line MV4-11 and acute myeloid leukemia cell line MOLM-13 were tested. Different concentrations of the two compounds (100nM, 200nM, 300nM, 400nM in DMSO) were used to act on acute myeloid leukemia cell lines MV4-11 and MOLM-13 carrying FLT3 / ITD mutation genes. After 24 hours, the cells were collected, washed twice with IXPBS buffer, fixed with 75% ethanol at -20°C for 24 hours, washed twice with IXPBS buffer, 0.5mL IXPBS buffer and 0.5mL PI staining solution (purchased from BD Bioscience, USA) were added to the cells and the cells were placed in the dark at 37°C for staining for 15 minutes, and the cell cycle distribution was detected by flow cytometry (BD FACS Calibur), and data analysis was performed using FlowJo software (Ashland OR).

[0084] The experimental results are as follows Figure 1 and Figure 2 As shown, MOLM-13 cells ( Figure 1 ) and MV4-11 cells ( Figure 2 ) Under the action of D18 and D18-D6, the cell cycle was arrested at the G0-G1 phase in a dose-dependent manner.

[0085] Effects of D18 and D18-D6 on cell clone formation

[0086] The proliferation ability of MOLM-13 and MV-4-11 cells carrying FLT3 / ITD mutant genes was detected by soft agar colony formation experiment. Different concentrations of two compounds (2.5nM, 5nM, 10nM, 20nM in DMSO) were used to act on MOLM-13 and MV-4-11 cell lines carrying FLT3 / ITD mutant genes. The time required for sufficient colony formation is usually 15 days, and the medium is changed twice a week.

[0087] The experimental results are as follows Figure 3 As shown, when the drug dose increased, the clones formed by MOLM-13 and MV4-11 cells were significantly reduced, and the number of colonies in the D18-D6 drug group was significantly reduced, indicating that D18-D6 has a stronger ability to reduce the proliferation of AML cells than D18.

[0088] D18 and D18-D6 in the treatment of acute myeloid leukemia

[0089] In order to detect the inhibitory effect on tumors in vivo, a nude mouse subcutaneous tumor-bearing model was introduced. More than 30 5-week-old mice (Balb / c-nu male mice, purchased from Hangzhou Ziyuan Experimental Animal Technology Co., Ltd.) were subcutaneously inoculated with 1×10 M0LM-13 cells. 7 The weight changes and tumor volume (tumor volume = tumor length × tumor width) of the mice were recorded daily. 2 / 2). After 10 days, when the tumor volume of mice reached 200-400mm 3 The mice were randomly divided into three groups: vehicle group, D18 50mg / kg group, and D18-D6 50mg / kg group, with 6-10 mice in each group. The following treatments were performed: the first group was orally administered with a vehicle (5% DMSO, 40% PEG-400, and 55% saline solution every day; the second group was orally administered with a D18 solution at 50mg / kg every day; the third group was orally administered with a D18-D6 solution at 50mg / kg every day. The first administration day was recorded as day 0, and the administration was continued for 2 to 3 weeks.

[0090] The experimental results are as follows Figure 4 As shown, Figure 4 A shows the changes in the body weight of mice after administration. Figure 4 B shows the changes in tumor size in mice after drug administration. Figure 4 C shows the actual photo of the final tumor in the mouse after drug administration. Figure 4D shows the final tumor weight in mice after administration. The results showed that after mice were treated with D18, the tumor growth of mice was significantly inhibited, and the growth of mouse tumor volume was significantly slowed down; after mice were treated with D18-D6, the tumor growth of mice was strongly inhibited; the growth of tumor volume of mice in the D18 group was significantly slowed down, and the tumor of mice in the D18-D6 group hardly grew. The data of the tumor transplantation mouse model showed that D18 and D18-D6 can inhibit the growth of acute myeloid leukemia (AML) tumors in mice, and the inhibitory effect of D18-D6 is significantly stronger than that of D18.

[0091] Differences in pharmacokinetics between D18 and D18-D6

[0092] The present invention also evaluated the pharmacokinetic PK characteristics of D18 and D18-D6 in rats administered intravenously and orally. The results are shown in Tables 2 and 3. The half-life of D18 is about 1.5 h for intravenous administration and about 3.6 h for po administration, and the bioavailability is about 35.93%; the half-life of D18-D6 is about 1.9 h for intravenous administration and about 4.3 h for po administration, and the bioavailability is about 42.51%, indicating that the pharmacokinetic characteristics of D18-D6 are significantly improved compared with D18.

[0093] Table 2 Pharmacokinetic properties of D18

[0094]

[0095] Table 3 Pharmacokinetic properties of D18-D6

[0096]

[0097] The term "deuterated" used in the present invention refers to one or more hydrogens in a compound or group being replaced by deuterium. Deuterated can be monosubstituted, disubstituted, polysubstituted or fully substituted. After deuterated, the deuterium isotope content of deuterium at the deuterium substituted position is greater than the natural deuterium isotope content (0.015%), more preferably greater than 50%, more preferably greater than 75%, more preferably greater than 95%, more preferably greater than 97%, more preferably greater than 99%, more preferably greater than 99.5%.

[0098] The term "pharmaceutically acceptable salt" used in the present invention refers to a salt suitable for use as a drug formed by the compound of the present invention and an acid or base. Pharmaceutically acceptable salts may include both inorganic salts and organic salts.

[0099] The term "active ingredient" as used in the present invention refers to any substance or mixture of substances used in the manufacture of pharmaceuticals, which has pharmacological activity or other direct effects in the diagnosis, treatment, symptom relief, management or prevention of diseases or can affect the function or structure of the body.

[0100] The term "pharmaceutically acceptable excipient" used in the present invention has certain physiological activity, but the addition of this component will not change the dominant position of the above-mentioned pharmaceutical composition in the treatment of the disease, but only play an auxiliary effect, which is only the utilization of the known activity of the component and is a conventional auxiliary treatment method in the medical field. If the above-mentioned auxiliary components are used in conjunction with the pharmaceutical composition of the present invention, they should still fall within the scope of protection of the present invention.

[0101] The above embodiments are exemplary, and their purpose is to illustrate the technical concept and features of the present invention so that people familiar with the technology in this field can understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. A compound or a pharmaceutically acceptable salt thereof, characterized in that: The compound is of formula (I):

2. A compound or a pharmaceutically acceptable salt thereof, characterized in that: The compound is of formula (II):

3. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, characterized in that: The pharmaceutically acceptable salt is a salt formed between the compound and an acid.

4. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, characterized in that: The pharmaceutically acceptable salt is selected from one or more of phosphate, camphorsulfonate, hydrochloride, hydrobromide, hydrofluoride, sulfate, nitrate, format, acetate, propionate, oxalate, malonate, succinate, fumarate, maleate, lactate, malate, tartrate, citrate, picrate, methanesulfonate, trifluoromethanesulfonate, toluenesulfonate, and benzenesulfonate.

5. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, characterized in that: The pharmaceutically acceptable salt is hydrochloride.

6. Use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, characterized in that: The compound or a pharmaceutically acceptable salt thereof is used in preparing a drug for treating cancer, wherein the cancer is leukemia.

7. Use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, characterized in that: The compound or a pharmaceutically acceptable salt thereof is used for preparing a FLT3 kinase inhibitor.

8. A drug for treating cancer, characterized in that: The drug is prepared by using the compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof as an active ingredient and adding pharmaceutically acceptable excipients, and the cancer is leukemia.